72PCemiplimab, a human monoclonal anti-PD-1, plus radiotherapy (RT) in advanced non-small cell lung cancer (NSCLC): Results from a phase I expansion cohort (EC 2). (17th December 2018) - Moreno, V; Gil-Martin, M; Johnson, M L; Aljumaily, R; Lopez Criado, P; Northfelt, D W; Crittenden, M; Jabbour, S; Rosen, L; Garrido, P; Hervás Morón, A; Rietschel, P; et al.